

UNIVERSITI TEKNOLOGI MARA

**EFFECTS OF STEVIOSIDE ON *IN-VITRO* ADIPOCYTE
DIFFERENTIATION**

MUHAMMAD FARHI BIN MD YUSOFF

BACHELOR OF PHARMACY (Hons.)

2015

ABSTRACT

Diabetes mellitus is characterized by insulin resistance leading to irregularities in protein, fat and carbohydrate metabolism. Commercially available drugs like metformin is commonly prescribed to treat Type 2 diabetes, though its usage is burdened by contraindications such as congestive heart failure, chronic obstructive pulmonary disease and chronic renal insufficiency. In accordance to this problem, *Stevia rebaudiana* Bertoni contains stevioside which is a potent bioactive compound to treat diabetes and has been suggested to benefit glucose metabolism. The purpose of this study is to investigate the inhibitory potentials of stevioside on 3T3-L1 adipocyte differentiation and lipid production. The methods used in this study include cell culture, cell differentiation, treatment with stevioside, Oil Red-O (ORO) staining and statistical analysis. The results showcased a significant difference, proving that stevioside possibly might possess the capability to inhibit adipocyte differentiation. As a conclusion, *Stevia rebaudiana* Bertoni might prove to play a vital role in the treatment of diabetes mellitus in the near future as this study has proven its potential to inhibit adipocyte differentiation.

ACKNOWLEDGEMENT

I would to convey my deepest gratitude to the supervisor of this study, Dr Wan Iryani bt Wan Ismail, for giving me advice, comments and assistance in the development of this thesis until it managed to be successfully completed. Very special thanks to one of her post-graduate students, Kak Nabilatul Hani Mohd-Radzman, for providing me guidance on how to perform the procedures, handle the laboratory equipment and also contributing some ideas during the process of laboratory work and data gathering throughout this study. My gratitude also extends to the laboratory staff of the Faculty of Pharmacy, UiTM Puncak Alam Campus for providing comfortable and functional laboratory facilities during the experimental work throughout the duration of this research. Last but not least, I would like to thank my parents and my siblings for their continued encouragement and support towards me which gave me the determination to complete this study.

TABLE OF CONTENT

TITLE AND SUB-TITLE	PAGE
Approval Sheet	
Abstract	ii
Acknowledgement	iii
List of Figures	vi
List of Tables	vi
CHAPTER 1: INTRODUCTION	
1.1 Introduction	1-3
1.2 Problem Statement	3
1.3 Objective	3
1.4 Significance of Study	3
1.5 Hypothesis	4
1.6 Scope of Study	4
CHAPTER 2: LITERATURE REVIEW	
2.1 <i>Stevia rebaudiana</i> Bertoni	5-6
2.2 Stevioside	7-8
2.3 Medical Uses of Stevioside	9-10
2.4 Insulin-Signalling Pathway	11-12
2.5 Insulin Resistance and Diabetes	13-14
2.6 Gene Expression	15
CHAPTER 3: RESEARCH METHODOLOGY	
3.1 Materials	16

CHAPTER 1: INTRODUCTION

1.1 Introduction

Diabetes is a global problem, punctuated by the fact that there will be a 69% increase in the number of adults with diabetes in developing countries between 2010 and 2030 (Table 1) (Shaw, Sicree, & Zimmet, 2010). The situation is no less worrisome in Malaysia where the prevalence of diabetes among individuals aged 18 years and older has experienced an increment from 11.6% in 2006 to 15.2% in 2011 (Kaur, Tee, Ariaratnam, Krishnapillai, & China, 2013). Characterized by insulin resistance which leads to irregularities in protein, fat and carbohydrate metabolism, diabetes can be categorized into two main groups: type I and type II. In Type I diabetes, the sugar is incapable of entering the cells in the body for energy metabolism due to the lack of insulin production by the pancreas. According to Ashcroft and Rorsman (2012), it is an autoimmune disease that results in β cell destruction, therefore depriving the pancreas of its ability to produce sufficient levels of insulin to regulate glucose uptake. Patients of type I diabetes typically require insulin injections to manage their blood glucose.

	2010		2030	
	Country	Prevalence (%)	Country	Prevalence (%)
1	Nauru	30.9	Nauru	33.4
2	United Arab Emirates	18.7	United Arab Emirates	21.4
3	Saudi Arabia	16.8	Mauritius	19.8
4	Mauritius	16.2	Saudi Arabia	18.9
5	Bahrain	15.4	Reunion	18.1
6	Reunion	15.3	Bahrain	17.3
7	Kuwait	14.6	Kuwait	16.9
8	Oman	13.4	Tonga	15.7
9	Tonga	13.4	Oman	14.9
10	Malaysia	11.6	Malaysia	13.8

Table 1: Top 10 countries for diabetes prevalence in 2010 and 2030 (Shaw *et al.*, 2010)